Blood cancers

PBS subsidy recommended for AML drug

A PBS listing has been recommended for midostaurin (Rydapt) in the treatment of FLT3 mutation positive acute myeloid leukaemia (AML). At its July meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) made a positive recommendation for a Section 100 (Highly Specialised Drugs Program) Authority Required listing of midostaurin for the treatment of patients with newly diagnosed ...

Already a member?

Login to keep reading.

© 2021 the limbic